Razelle Kurzrock, MD, FACP

Publications

• SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.

  (Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R.) Cancer. 2024 Sep 01;130(17):2918-2927 PMID: 38358334 PMCID: PMC11309904 SCOPUS ID: 2-s2.0-85185668211 02/15/2024

• Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.

  (Williams EA, Vegas I, El-Senduny FF, Zhang J, Mata DA, Hiemenz MC, Hughes SR, Sa BC, Kraft GP, Gorbatov N, Foley-Peres K, Sanchez EZ, Milikowski C, Williams KJ, Ross JS, Kurzrock R, Montgomery EA, Lombard DB, Kumar S.) Am J Surg Pathol. 2024 Jun 01;48(6):699-707 PMID: 38369783 PMCID: PMC11093512 SCOPUS ID: 2-s2.0-85193310997 02/19/2024

• Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.

  (Nishizaki D, Kurzrock R, Miyashita H, Adashek JJ, Lee S, Nikanjam M, Eskander RN, Patel H, Botta GP, Nesline MK, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kato S.) ESMO Open. 2024 Apr;9(4):102942 PMID: 38503143 PMCID: PMC10966162 SCOPUS ID: 2-s2.0-85188048929 03/20/2024

• Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.

  (Fountzilas E, Tsimberidou AM, Hiep Vo H, Kurzrock R.) Cancer Treat Rev. 2024 Apr;125:102703 PMID: 38484408 SCOPUS ID: 2-s2.0-85187942575 03/15/2024

• Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.

  (Fujiwara Y, Kato S, Kurzrock R.) Surg Oncol Clin N Am. 2024 Apr;33(2):197-216 PMID: 38401905 PMCID: PMC10894322 SCOPUS ID: 2-s2.0-85180341239 02/25/2024

• Outcome differences by sex in oncology clinical trials.

  (Kammula AV, Schäffer AA, Rajagopal PS, Kurzrock R, Ruppin E.) Nat Commun. 2024 Mar 23;15(1):2608 PMID: 38521835 PMCID: PMC10960820 SCOPUS ID: 2-s2.0-85188449657 03/24/2024

• Challenges to genetic testing for germline mutations associated with breast cancer among African Americans.

  (Kamaraju S, Conroy M, Harris A, Georgen M, Min H, Powell M, Kurzrock R.) Cancer Treat Rev. 2024 Mar;124:102695 PMID: 38325071 SCOPUS ID: 2-s2.0-85183959255 02/08/2024

• Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.

  (Adashek JJ, Pandya C, Maragakis NJ, De P, Cohen PR, Kato S, Kurzrock R.) BMC Med. 2024 Feb 19;22(1):74 PMID: 38369520 PMCID: PMC10875826 SCOPUS ID: 2-s2.0-85185507573 02/19/2024

• OX40/OX40 ligand and its role in precision immune oncology

  (Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R.) Cancer and Metastasis Reviews. September 2024;43(3):1001-1013 SCOPUS ID: 2-s2.0-85188533068 09/01/2024

• Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer

  (Shreenivas A, Nishizaki D, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Kato S, Kurzrock R.) International Journal of Molecular Sciences. May 2024;25(9) SCOPUS ID: 2-s2.0-85192758543 05/01/2024

• High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

  (Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Conroy JM, DePietro P, Pabla S, Lippman SM, Kurzrock R.) iScience. 19 April 2024;27(4) SCOPUS ID: 2-s2.0-85189797143 04/19/2024

• If it's a target, it's a pan-cancer target: Tissue is not the issue

  (Adashek JJ, Kato S, Sicklick JK, Lippman SM, Kurzrock R.) Cancer Treatment Reviews. April 2024;125 SCOPUS ID: 2-s2.0-85188673828 04/01/2024